NHL Clinical Trials

41 clinical trials for NHL across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma — RECRUITING · PHASE2
• JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma — RECRUITING · PHASE1
• IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers — RECRUITING · PHASE1
• A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies — RECRUITING · PHASE1
• A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS — RECRUITING · PHASE1
• Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL — RECRUITING · PHASE2
• Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients — RECRUITING · PHASE1
• A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE2
• Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies — COMPLETED · PHASE1
• Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies — COMPLETED · PHASE1
• The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL — ACTIVE_NOT_RECRUITING · PHASE2
• A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System — NOT_YET_RECRUITING · PHASE1
• PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) — TERMINATED · PHASE1
• Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma — TERMINATED · PHASE1
• FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL — COMPLETED · PHASE1
• CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma — NOT_YET_RECRUITING · PHASE2
• A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) — ACTIVE_NOT_RECRUITING · PHASE1
• First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML — TERMINATED · PHASE1
• A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients — OTHER
• Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies — TERMINATED · PHASE1
• A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL — WITHDRAWN · PHASE1
• HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL — WITHDRAWN · PHASE1
• Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) — COMPLETED · PHASE1
• A Study of IGN002 for Refractory NHL — WITHDRAWN · PHASE1
• Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL — WITHDRAWN · PHASE1
• Safety Study of NHL With 90Y-hLL2 IgG — COMPLETED · PHASE1
• Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL — COMPLETED · PHASE1
• Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. — OTHER · PHASE1
• Influence of Corn Farming on the Immune System — COMPLETED
• Allogeneic Transplantation From Related Haploidentical Donors — COMPLETED · PHASE2
• Safety and Efficacy Evaluation of Decitabine With R-GDP — OTHER · PHASE1
• An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies — TERMINATED · PHASE1
• Umbilical Cord Blood Transplant for Hematological Malignancies — COMPLETED · PHASE1
• Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft — TERMINATED · PHASE1
• Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia — COMPLETED
• CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation — COMPLETED · NA
• Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 — TERMINATED · PHASE1
• Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease — OTHER · PHASE1

Refine this search